Cerniglia Brett, Judson Marc A
Department of Medicine, Albany Medical College, Albany, NY 12208, USA.
Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, NY 12208, USA.
Case Rep Med. 2013;2013:216939. doi: 10.1155/2013/216939. Epub 2013 Nov 19.
We report a patient with cutaneous sarcoidosis who developed hypothyroidism following 17 months of infliximab therapy. To our knowledge, this is the first reported case of hypothyroidism following infliximab administration. While it is possible that the patient's hypothyroidism was unrelated to the use of infliximab, the time course and lack of alternative explanations make such an association plausible. We postulate that hypothyroidism in this patient may have been related to the development of autoantibodies to infliximab that triggered the development of an autoimmune thyroiditis. Regardless of the mechanism, we would encourage clinicians to keep the potential mechanisms of TNF-α in mind when treating patients with TNF-α antagonist medications.
我们报告了一名皮肤结节病患者,在接受英夫利昔单抗治疗17个月后出现甲状腺功能减退。据我们所知,这是首例报道的英夫利昔单抗给药后发生甲状腺功能减退的病例。虽然患者的甲状腺功能减退可能与英夫利昔单抗的使用无关,但时间进程以及缺乏其他解释使得这种关联看似合理。我们推测该患者的甲状腺功能减退可能与针对英夫利昔单抗的自身抗体的产生有关,这些自身抗体引发了自身免疫性甲状腺炎的发展。无论机制如何,我们鼓励临床医生在使用肿瘤坏死因子-α拮抗剂药物治疗患者时牢记肿瘤坏死因子-α的潜在作用机制。